Palonosetron hydrochloride in the prevention and treatment of postoperative nausea and vomiting

Clinical Medicine Insights: Therapeutics

Volumn 2, Issue , 2010, Pages 387-399

  Wallenborn, Jan ^a   Kranke, Peter ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Nausea; Palonosetron; Postoperative; Vomiting

Indexed keywords

ANALGESIC AGENT; ANTIEMETIC AGENT; APREPITANT; CALCIUM ION; DEXAMETHASONE; DOLASETRON MESILATE; DRUG METABOLITE; GRANISETRON; METOCLOPRAMIDE; ONDANSETRON; PALONOSETRON; PARACETAMOL; PLACEBO; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; TRAMADOL; TROPISETRON;

AKATHISIA; ANALGESIA; BONE NECROSIS; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DYSPEPSIA; ELECTROCARDIOGRAM; ETHNICITY; EXTRAPYRAMIDAL SYMPTOM; GENERAL ANESTHESIA; GENETIC POLYMORPHISM; HIGH RISK PATIENT; HOLTER MONITORING; HOT FLUSH; HUMAN; HYPERTENSIVE CRISIS; HYPOTENSION; HYSTERECTOMY; INJECTION SITE BURNING; INJECTION SITE DISCOMFORT; INJECTION SITE PAIN; POSTOPERATIVE NAUSEA AND VOMITING; POSTOPERATIVE PERIOD; QT INTERVAL; QT PROLONGATION; RECEPTOR AFFINITY; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; TACHYCARDIA; WOUND HEALING IMPAIRMENT;

EID: 77952680723     PISSN: None     EISSN: 1179559X     Source Type: Journal    
DOI: 10.4137/cmt.s4016     Document Type: Review

References (70)

1. Macario A, Weinger M, Carney S, Kim A. Which clinical anesthesia outcomes are important to avoid? The perspective of patients. Anesth Analg. 1999;89:652-8.
2. Eberhart LHJ, Morin AM, Wulf H, Geldner G. Patient preferences for immediate postoperative recovery. Br J Anaesth. 2002;89:760-1.
3. Gan T, Sloan F, Dear GL, El-Moalem HE, Lubarsky DA. How much are patients willing to pay to avoid postoperative nausea and vomiting? Anesth Analg. 2001;92:393-400.
4. Kerger H, Turan A, Kredel M, et al. Patients' willingness to pay for antiemetic treatment. Acta Anaesthesiol Scand. 2007;51:38-43.
5. Koivuranta M, Läärä E, Snåre L, Alahuhta S. A survey of postoperative nausea and vomiting. Anaesthesia. 1997;52:443-9.
6. Apfel CC, Läärä E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting. Anesthesiology. 1999;91:693-700.
7. Kranke P, Schuster F, Eberhart LH. Recent advances, trends and economic considerations in the risk assessment, prevention and treatment of postoperative nausea and vomiting. Expert Opin Pharmacother. 2007;8:1-19.
8. Col C, Soran A, Col M. Can postoperative abdominal wound dehiscence be predicted? Tokai J Exp Clin Med. 1998;23:123-7.
9. Baric A. Oesophageal rupture in a patient with postoperative nausea and vomiting. Anaesth Intens Care. 2000;28:325-7.
10. Atallah FN, Riu BM, Nguyen LB, Seguin PO, Fourcade OA. Boerhave's Syndrome after postoperative vomiting. Anesth Analg. 2004;98:1164-6.
11. Nanji GM, Maltby JR. Vomiting and aspiration pneumonitis with the laryngeal mask airway. Can J Anaesth. 1992;39:69-70.
12. Bremner WG, Kumar CM. Delayed surgical emphysema, pneumomediastinum and bilateral pneumothoraces after postoperative vomiting. Br J Anaesth. 1993;71:296-7.
13. Schumann R, Polaner DM. Massive subcutaneous emphysema and sudden airway compromise after postoperative vomiting. Anesth Analg. 1999;89:796-7.
14. Toprak V, et al. Subcutaneous emphysema following severe vomiting after emerging from general anaesthesia. Acta Anaesthesiol Scand. 2004;48:917-8.
15. Irefin SA, Frid IS, Senagore AJ. Urgent colectomy in a patient with membranous tracheal disruption after severe vomiting. Anesth Analg. 2000;91:1300-2.
16. Elfar A, Barnes SD. A real eye-opener! Anesth Analg. 2000;90:1003-4.
17. Zhang GS, Mathura JR Jr. Images in clinical medicine. Painless loss of vision after vomiting. N Engl J Med. 2005;352:e16.
18. Gold BS, Kitz DS, Lecky JH, Neuhaus JM. Unanticipated admission to the hospital following ambulatory surgery. JAMA. 1989;262:3008-10.
19. Gan TJ, Meyer TA, Apfel CC, et al. Society for Ambulatory Anesthesia guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2007;105:1615-28.
20. Apfel CC, Kranke P, Piper S, et al. Nausea and vomiting in the postoperative phase. Expert- and evidence-based recommendations for prophylaxis and therapy. Anaesthesist. 2007;56:1170-80 [Article in German].
21. Palazzo M, Evans R. Logistic regression analysis of fixed patient factors for postoperative sickness. A model of risk assessment. Br J Anaesth. 1993;70:135-40.
22. Sinclair DR, Chung F, Mezei G. Can postoperative nausea and vomiting be predicted? Anesthesiology. 1999;91:109-18.
23. Junger A, Hartmann B, Benson M, et al. The use of an anesthesia information management system for prediction of antiemetic rescue treatment at the postanesthesia care unit. Anesth Analg. 2001;92:1203-9.
24. Eberhart LHJ, Geldner G, Kranke P, et al. The development and validation of a risk score to predict the probability of postoperative vomiting in pediatric patients. Anesth Analg. 2004;99:1630-7.
25. Kranke P, Eberhart LH, Toker H, Roewer N, Wulf H, Kiefer P. A prospective evaluation of the POVOC score for the prediction of postoperative vomiting in children. Anesth Analg. 2007;105:1592-7.
26. Tramer MR. Postoperative Übelkeit und Erbrechen. Anaesthesist. 2007; 56:679-85.
27. Apfel CC, Korttila K, Abdalla M, et al. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med. 2004;350:2441-51.
28. White PF, ÓHara JF, Roberson CR, Wender RH, Candiotti KA. The impact of current antiemetic practises on patient outcomes: a prospective study on high-risk patients. Anesth Analg. 2008;107:452-8.
29. Reavley CM, Cherkas L, Spector TD, MacGregor AJ. Genetic factors contribute to the risk of postoperative nausea and vomiting: results of a twin study. Br J Anaesth. 1999;82:1-2.
30. Ho KY, Gan TJ. Pharmacology, pharmacogenetics, and clinical efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Curr Opin Anaesth. 2006;19:606-11.
31. 3 receptor antagonists. Pharmacogenetics. 2004;14:271-8.
32. Tremblay PB, Kaiser R, Sezer O, et al. Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol. 2003;21:2147-55.
33. 3B serotonin receptor genes (HTR3A and HTR3B) influence the occurrence of postoperative vomiting? Anesth Analg. 2009;109:1442-7.
34. Babaoglu MO, Bayar B, Aynacioglu AS, et al. Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists. Clin Pharmacol Ther. 2005;78:619-26.
35. Carlisle JB, Stevenson CA. Drugs for preventing nausea and vomiting after surgery. Cochrane Review. 2006;CD004125.
36. Wallenborn J, Gelbrich G, Bulst D, et al. Prevention of postoperative nausea and vomiting by metoclopramide combined with dexamethasone-a randomised double-blind multicentre trial. BMJ. 2006;333:324-7.
37. Kranke P, Morin A, Vogel H, Kranke E, Roewer N, Eberhart L. Clinical and economic efficiency of approaches to prevent PONV. Anesth Analg. 2006;102:S133.
38. Kranke P, Schuster F, Eberhart LH. Recent advances, trends and economic considerations in the risk assessment, prevention and treatment of postoperative nausea and vomiting. Expert Opin Pharmacother. 2007;8:1-19.
39. American Society of Anesthesiologists Task Force on Postanesthetic Care. Practice guidelines for postanesthetic care. Anesthesiology. 2002;96:742-52.
40. American Society of PeriAnesthesia Nurses PONV/PDNV Strategic Work Team. ASPAN's evidence-based clinical practice guideline for the prevention and/or management of PONV. J Perianesth Nurs. 2006;21:230-50.
41. Association of Paediatric Anaesthetists of Great Britain and Ireland. Guidelines for the prevention of postoperative vomiting in children. 2008. available from http://www.apagbi.org.uk, Accessed: October 26, 2009.
42. Diemunsch P. Société française d'anesthésie et de reanimation. Conference of experts-short text. Management of postoperative nausea and vomiting. French Society of Anesthesia and Resuscitation. Ann Fr Anesth Reanim. 2008;27:866-78.
43. McCracken G, Houston P, Lefebvre G; Society of Obstetricians and Gynecologists of Canada. Guideline for the management of postoperative nausea and vomiting. J Obstet Gynaecol Can. 2008;30:600-16.
44. White PF, O'Hara JF, Roberson CR, Wender RH, Candiotti KA; POST-OP Study Group. The impact of current antiemetic practices on patient outcomes: a prospective study on high-risk patients. Anesth Analg. 2008;107:452-8.
45. 3 receptor. Anesth Analg. 2008;107:469-78.
46. 3 receptor network after 20 years of research-evolving concepts in management of pain and inflammation. Eur J Pharmacol. 2007;560:1-8.
47. 3 receptor as a therapeutic agent. Expert Opin Ther Targets. 2007;11:527-40.
48. Helsinn Healthcare SA. Prescribing Information: ALOXI® (palonosetron HCl) injection for intravenous use. 2008. Available at http://www.aloxi.com/PrescribingInformation.aspx, Accessed: October 26 2009.
49. 3 receptors, in vitro. Br J Pharmacol. 1995;114:851-9.
50. Stoltz R, Cyong JC, Shah A, Parisi S. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. J Clin Pharmacol. 2004;44:520-31.
51. Jordan K, Schmoll HJ, Aapro MS. Comparative activity of antiemetic drugs. Critical Reviews in Oncology/Hematology. 2007;61:162-75.
52. 3-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment. Oncology. 2005;69:97-109.
53. Stoltz R, Parisi S, Shah A, Macciocchi A. Pharmacokinetics, metabolism and excretion of intravenous [l4C]-palonosetron in healthy human volunteers. Biopharm Drug Dispos. 2004;25:329-37.
54. 3 receptor antagonist. Results of a phase III, single-dose trial versus dolasetron. Cancer. 2003;98:2473-82.
55. Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: Results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003;14:1570-7.
56. Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethsone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomized, comparative phase III trial. Lancet Oncol. 2009;10:115-24.
57. Yu Z, Liu W, Wang L, et al. The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial. Support Care Cancer. 2009;17:99-102.
58. Kovac AL, Eberhart L, Kotarski J, et al. A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo in preventing postoperative nausea and vomiting over a 72-hour period. Anesth Analg. 2008;107:439-44.
59. Candiotti KA, Kovac AL, Melson TI, et al. A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo for preventing postoperative nausea and vomiting. Anesth Analg. 2008;107:445-51.
60. 3 receptor antagonist, for preventing postoperative nausea and vomiting after hysterectomy procedures. Anesth Analg. 1998;87:462-7.
61. Chelly J, Melson T, Pollock J, Hantler C. Oral RS-25259 prevents postoperative nausea and vomiting following laparoscopic surgery. Anesthesiology. 1996;85:3A,A21.
62. 3 receptor antagonist. Anesthesiology. 2005;103:A703.
63. Kolodzie K, Apfel CC. Nausea and vomiting after office-based anesthesia. Curr Opin Anaesthesiol. 2009;22:532-8.
64. Helsinn Healthcare SA. Safety and efficacy of palonosetron IV to prevent postoperative nausea and vomiting in pediatric patients. 2009. Available at http://clinicaltrials.gov/ct2/show/NCT00828295, Accessed: October 30, 2009.
65. 3 antagonists with dexamethasone or droperidol for prevention of PONV. Ann Pharmacother. 2006;40:856-72.
66. Wallenborn J, Eberhart L, Kranke P. Postoperative nausea and vomiting. What's new in anti-emetic pharmacotherapy? Anästhesiol Intensivmed Not- fallmed Schmerzther. 2009;44:296-305.
67. Shah A, DeGroot T, Apseloff G. Pharmacokinetic evaluation and safety profile of a 15-minute versus 30-second infusion of palonosetron in healthy subjects. J Clin Pharmacol. 2006;46:1139-45.
68. Muchatuta NA, Paech MJ. Management of postoperative nausea and vomiting: focus on palonosetron. Therapeutics and Clinical Risk Management. 2009;5:21-34.
69. 3 spinal receptor involvement in acute pain in humans. Anesth Analg. 2002;94:1553-7.
70. Pickering G, Loriot MA, Libert F, et al. Analgesic effect of acetaminophen in humans: first evidence of a central serotonergic mechanism. Clin Pharmacol Ther. 2006;79:371-8.